|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/192 | (2006.01) |
| A61P 1/16 | (2006.01) | ||
| A61K 9/00 | (2006.01) | ||
| A61K 45/06 | (2006.01) |
| (11) | Number of the document | 3435996 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17713332.9 |
| Date of filing the European patent application | 2017-03-30 | |
| (97) | Date of publication of the European application | 2019-02-06 |
| (45) | Date of publication and mention of the grant of the patent | 2025-04-30 |
| (46) | Date of publication of the claims translation | 2025-06-25 |
| (86) | Number | PCT/EP2017/057634 |
| Date | 2017-03-30 |
| (87) | Number | WO 2017/167935 |
| Date | 2017-10-05 |
| (30) | Number | Date | Country code |
| 16305381 | 2016-03-31 | EP |
| (72) |
HANF, Rémy , FR
|
| (73) |
Genfit ,
885, Avenue Eugène Avinée, 59120 Loos,
FR
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Elafibranoras, skirtas panaudoti gydant pirminį tulžies latakų cholangitą |
| ELAFIBRANOR FOR USE IN THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS |
| Payment date | Validity (years) | Amount | |
| 2026-02-24 | 10 | 231.00 EUR |
| 2027-03-30 |